Patents by Inventor Benoit L'Archeveque
Benoit L'Archeveque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9471706Abstract: System and method are disclosed for refining a semantic search query through large quantities of dynamically created concept categories and their associated extracted values on a mobile device using only two filtering controls or buttons. The first filtering control is a Semantic Categorization Filter control and the second filtering control is a Semantic Categorization Selection control. The user queries a semantic search engine using text or voice controls. The results returned to the user imply the full scope of search results along with a dynamically created semantic categorization. The most relevant semantic categorization will be considered as the pre-selected category in the Semantic Categorization Filter control along with a list of possible dynamically created sub-categorizations and the Semantic Categorization Selection control will be pre-populated with other possible semantic categorizations of the result set.Type: GrantFiled: March 7, 2012Date of Patent: October 18, 2016Assignee: AZZIMOV INC.Inventors: Benoit L'Archeveque, Mickael Camus, Denton Cockburn, Richard Pavy, Lise Rebout, Anthony Bryant
-
Publication number: 20130346398Abstract: System and method are disclosed for refining a semantic search query through large quantities of dynamically created concept categories and their associated extracted values on a mobile device using only two filtering controls or buttons. The first filtering control is a Semantic Categorization Filter control and the second filtering control is a Semantic Categorization Selection control. The user queries a semantic search engine using text or voice controls. The results returned to the user imply the full scope of search results along with a dynamically created semantic categorization. The most relevant semantic categorization will be considered as the pre-selected category in the Semantic Categorization Filter control along with a list of possible dynamically created sub-categorizations and the Semantic Categorization Selection control will be pre-populated with other possible semantic categorizations of the result set.Type: ApplicationFiled: March 7, 2012Publication date: December 26, 2013Inventors: Benoit L'Archeveque, Mickael Camus, Denton Cockburn, Richard Pavy, Lise Rebout, Anthony Bryant
-
Patent number: 8093206Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: December 14, 2005Date of Patent: January 10, 2012Assignee: Conjuchem, LLCInventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 8084414Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: August 30, 2005Date of Patent: December 27, 2011Assignee: Conjuchem, LLCInventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 8080516Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: June 29, 2005Date of Patent: December 20, 2011Assignee: Conjuchem, LLCInventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk LeBlanc, Serge St. Pierre
-
Publication number: 20090093408Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a react group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: ApplicationFiled: August 1, 2008Publication date: April 9, 2009Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20090075890Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: August 1, 2008Publication date: March 19, 2009Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060135426Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: December 14, 2005Publication date: June 22, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L' Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060058235Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: August 30, 2005Publication date: March 16, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060009377Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: June 29, 2005Publication date: January 12, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge Pierre
-
Patent number: 6887849Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: May 3, 2005Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6821949Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: November 23, 2004Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20040138100Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 25, 2003Publication date: July 15, 2004Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L' Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20040127398Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 25, 2003Publication date: July 1, 2004Applicant: CONJUCHEM, INC.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6593295Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: June 6, 2001Date of Patent: July 15, 2003Assignee: Conjuchem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20030108568Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 4, 2002Publication date: June 12, 2003Inventors: Dominique P. Bridon, Benoit L' Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20030108567Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 4, 2002Publication date: June 12, 2003Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6514500Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: September 7, 2000Date of Patent: February 4, 2003Assignee: Conjuchem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20020049153Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: June 6, 2001Publication date: April 25, 2002Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6329336Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: September 5, 2000Date of Patent: December 11, 2001Assignee: Conjuchem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre